Skip to main content
. 2022 Apr 29;9:879355. doi: 10.3389/fcvm.2022.879355

Figure 2.

Figure 2

Effects of LDL-C lowering drugs or genetic variants on glucose metabolism. LDL-C lowering drugs or genetic variants disturb glucose homeostasis via multiple ways. Genetic PCSK9 deficiency impairs pancreatic β-cell insulin secretion while NPC1L1 inhibitors and genetic NPC1L1 deficiency lead to insulin resistance of hepatocyte. HMGCR inhibitors and genetic HMGCR deficiency impairs pancreatic β-cell insulin secretion and induce insulin resistance of skeletal muscle cell, adipocyte, and hepatocyte.